1. Haffner SM, Lehto S, Ronnemaa T, Pyorala K, Laakso M. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med 1998;339:229-234.
PubMed
2. Anavekar NS, McMurray JJ, Velazquez EJ, Solomon SD, Kober L, Rouleau JL, White HD, Nordlander R, Maggioni A, Dickstein K, Zelenkofske S, Leimberger JD, Califf RM, Pfeffer MA. Relation between renal dysfunction and cardiovascular outcomes after myocardial infarction. N Engl J Med 2004;351:1285-1295.
PubMed
3. Manjunath G, Tighiouart H, Coresh J, Macleod B, Salem DN, Griffith JL, Levey AS, Sarnak MJ. Level of kidney function as a risk factor for cardiovascular outcomes in the elderly. Kidney Int 2003;63:1121-1129.
PubMed
4. Aso Y. Cardiovascular disease in patients with diabetic nephropathy. Curr Mol Med 2008;8:533-543.
PubMed
5. Stevens LA, Coresh J, Greene T, Levey AS. Assessing kidney function: measured and estimated glomerular filtration rate. N Engl J Med 2006;354:2473-2483.
PubMed
6. Grubb A. Diagnostic value of analysis of cystatin C and protein HC in biological fluids. Clin Nephrol 1992;38(Suppl 1):S20-S27.
PubMed
7. Randers E, Erlandsen EJ. Serum cystatin C as an endogenous marker of the renal function: a review. Clin Chem Lab Med 1999;37:389-395.
PubMed
8. Dharnidharka VR, Kwon C, Stevens G. Serum cystatin C is superior to serum creatinine as a marker of kidney function: a meta-analysis. Am J Kidney Dis 2002;40:221-226.
PubMed
9. Laterza OF, Price CP, Scott MG. Cystatin C: an improved estimator of glomerular filtration rate? Clin Chem 2002;48:699-707.
PubMed
10. Mussap M, Dalla Vestra M, Fioretto P, Saller A, Varagnolo M, Nosadini R, Plebani M. Cystatin C is a more sensitive marker than creatinine for the estimation of GFR in type 2 diabetic patients. Kidney Int 2002;61:1453-1461.
PubMed
11. Shimizu-Tokiwa A, Kobata M, Io H, Kobayashi N, Shou I, Funabiki K, Fukui M, Horikoshi S, Shirato I, Saito K, Tomino Y. Serum cystatin C is a more sensitive marker of glomerular function than serum creatinine. Nephron 2002;92:224-226.
PubMed
12. Shlipak MG, Sarnak MJ, Katz R, Fried LF, Seliger SL, Newman AB, Siscovick DS, Stehman-Breen C. Cystatin C and the risk of death and cardiovascular events among elderly persons. N Engl J Med 2005;352:2049-2060.
PubMed
13. Jernberg T, Lindahl B, James S, Larsson A, Hansson LO, Wallentin L. Cystatin C: a novel predictor of outcome in suspected or confirmed non-ST-elevation acute coronary syndrome. Circulation 2004;110:2342-2348.
PubMed
14. Keller T, Messow CM, Lubos E, Nicaud V, Wild PS, Rupprecht HJ, Bickel C, Tzikas S, Peetz D, Lackner KJ, Tiret L, Munzel TF, Blankenberg S, Schnabel RB. Cystatin C and cardiovascular mortality in patients with coronary artery disease and normal or mildly reduced kidney function: results from the Athero-Gene study. Eur Heart J 2009;30:314-320.
PubMed
15. Tenstad O, Roald AB, Grubb A, Aukland K. Renal handling of radiolabelled human cystatin C in the rat. Scand J Clin Lab Invest 1996;56:409-414.
PubMed
16. Abrahamson M, Olafsson I, Palsdottir A, Ulvsback M, Lundwall A, Jensson O, Grubb A. Structure and expression of the human cystatin C gene. Biochem J 1990;268:287-294.
PubMed PMC
17. Price CP, Finney H. Developments in the assessment of glomerular filtration rate. Clin Chim Acta 2000;297:55-66.
PubMed
18. Bokenkamp A, Domanetzki M, Zinck R, Schumann G, Byrd D, Brodehl J. Cystatin C: a new marker of glomerular filtration rate in children independent of age and height. Pediatrics 1998;101:875-881.
PubMed
19. Menon V, Shlipak MG, Wang X, Coresh J, Greene T, Stevens L, Kusek JW, Beck GJ, Collins AJ, Levey AS, Sarnak MJ. Cystatin C as a risk factor for outcomes in chronic kidney disease. Ann Intern Med 2007;147:19-27.
PubMed
20. Ix JH, Shlipak MG, Chertow GM, Whooley MA. Association of cystatin C with mortality, cardiovascular events, and incident heart failure among persons with coronary heart disease: data from the heart and soul study. Circulation 2007;115:173-179.
PubMed
21. Shlipak MG, Katz R, Sarnak MJ, Fried LF, Newman AB, Stehman-Breen C, Seliger SL, Kestenbaum B, Psaty B, Tracy RP, Siscovick DS. Cystatin C and prognosis for cardiovascular and kidney outcomes in elderly persons without chronic kidney disease. Ann Intern Med 2006;145:237-246.
PubMed
22. Muntner P, Mann D, Winston J, Bansilal S, Farkouh ME. Serum cystatin C and increased coronary heart disease prevalence in US adults without chronic kidney disease. Am J Cardiol 2008;102:54-57.
PubMed
23. Knight EL, Verhave JC, Spiegelman D, Hillege HL, de Zeeuw D, Curhan GC, de Jong PE. Factors influencing serum cystatin C levels other than renal function and the impact on renal function measurement. Kidney Int 2004;65:1416-1421.
PubMed
24. Leung-Tack J, Tavera C, Gensac MC, Martinez J, Colle A. Modulation of phagocytosis-associated respiratory burst by human cystatin C: role of the N-terminal tetrapeptide Lys-Pro-Pro-Arg. Exp Cell Res 1990;188:16-22.
PubMed
25. Bokenkamp A, Herget-Rosenthal S, Bokenkamp R. Cystatin C, kidney function and cardiovascular disease. Pediatr Nephrol 2006;21:1223-1230.
PubMed
26. Taglieri N, Koenig W, Kaski JC. Cystatin C and cardiovascular risk. Clin Chem 2009;55:1932-1943.
PubMed
27. Maahs DM, Ogden LG, Kretowski A, Snell-Bergeon JK, Kinney GL, Berl T, Rewers M. Serum cystatin C predicts progression of subclinical coronary atherosclerosis in individuals with type 1 diabetes. Diabetes 2007;56:2774-2779.
PubMed
28. Ogawa Y, Goto T, Tamasawa N, Matsui J, Tando Y, Sugimoto K, Tomotsune K, Kimura M, Yasujima M, Suda T. Serum cystatin C in diabetic patients. Not only an indicator for renal dysfunction in patients with overt nephropathy but also a predictor for cardiovascular events in patients without nephropathy. Diabetes Res Clin Pract 2008;79:357-361.
PubMed
29. Lee SH, Lee KW, Kim ES, Park YR, Kim HS, Park SA, Kang MJ, Ahn YB, Yoon KH, Cha BY, Son HY, Kwon HS. Cystatin C is a valuable marker for predicting future cardiovascular disease in type 2 diabetic patients. Korean Diabetes J 2008;32:488-497.
30. Luc G, Bard JM, Lesueur C, Arveiler D, Evans A, Amouyel P, Ferrieres J, Juhan-Vague I, Fruchart JC, Ducimetiere P. PRIME Study Group. Plasma cystatin-C and development of coronary heart disease: The PRIME study. Atherosclerosis 2006;185:375-380.
PubMed